Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00311311 · ClinicalTrials.gov registry record · Phase 3
Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 72
- Enrollment target
NCT00311311 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 72 participants.
The verdict
NCT00311311, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether immunosuppression by tacrolimus, mycophenolate mofetil, and prednisone compared to conversion to sirolimus, mycophenolate mofetil, and prednisone affect the progression of atherosclerosis in renal transplant recipients.
Interventions
- DRUG prednisone
- DRUG tacrolimus
- DRUG sirolimus
- DRUG mycophenolate mofetil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2006-04 |
| Est. Completion | 2012-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00311311
The ClinicalTrials.gov registry entry for NCT00311311 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which prednisone is the first listed.
NCT00311311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00311311 about?
NCT00311311 is a clinical study titled "Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients". The purpose of this study is to determine whether immunosuppression by tacrolimus, mycophenolate mofetil, and prednisone compared to conversion to sirolimus, mycophenolate mofetil, and prednisone affect the progression of atherosclerosis in renal transplant recipients.
What is the current status of trial NCT00311311?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 72 participants. The study started on 2006-04. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00311311?
The interventions under investigation include: prednisone (DRUG), tacrolimus (DRUG), sirolimus (DRUG), mycophenolate mofetil (DRUG).
Who is sponsoring clinical trial NCT00311311?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.